Je was op zoek naar: bound (Engels - Maltees)

medium-bound
livell medju

in bundles firmly bound
fi gzuz marbutin sewwa

b bound fraction (immunoassays)
b ishma marbuta (immunoprovi)

article 4 consent to be bound
artikolu 4 kunsens ta' rbit

extent and nature of bound residues
grad u natura tal-fdalijiet magħqudin

budgetary problems were bound to arise.
ma setgħux ma jinħolqux problemi baġitarji.

ambrisentan is highly plasma protein bound.
ambrisentan jintrabat ħafna mal-proteini tal-plażma.

the united kingdom shall be bound by:
ir-renju unit jkun marbut b:

dasabuvir is highly bound to plasma proteins.
dasabuvir huwa marbut ħafna mal-proteini tal-plażma.

medicinal products highly bound to plasma protein
prodotti mediċinali li jingħaqdu b’qawwa ma’ proteina fil-plażma

about 2% of dexrazoxane is protein-bound.
madwar 2 % ta’ dexrazoxane huwa marbut mal-proteini.

article 76 action manifestly bound to fail . . . ................ ................ ....................
artikolu 76 rikors manifestament inammissibbli . . ............. ............. .....................

alogliptin is 20-30% bound to plasma proteins.
alogliptin huwa 20-30% marbut ma’ proteini tal-plażma.

liraglutide is extensively bound to plasma proteins (>98%).
liraglutide jintrabat b’mod estensiv mal-proteini fil-plażma (>98%).

free non-bound lutetium-177 should be consequently minimised.
konsegwentement lutetium-177 ħieles mhux marbut għandu jkun minimizzat.

69.3 % respectively, lower confidence bound -11.9%).
69.3 % rispettivament, limitu ta’ kunfidenza l-aktar baxx ta’ -11.9%).

ombitasvir was approximately 99.9% bound to human plasma proteins.
madwar 99.9% mill-ombitasvir kien marbut mal-proteini fil-plażma tal- bniedem..

paritaprevir was approximately 97-98.6% bound to human plasma proteins.
madwar 97-98.6% mill- paritaprevir kien marbut mal-proteini fil-plażma tal-bniedem.

lack of pharmacokinetics interaction bounds 50-200%.
medda ta’ 50-200% li fiha ma jseħħu l-ebda interazzjonijiet farmakokinetiċi